Anti-tumor efficacy and pre-clinical immunogenicity of IFNα2a-NGR

Regulatory Toxicology and Pharmacology

Volumn 60, Issue 1, 2011, Pages 73-78

  Zhang, Baolai ^a,b   Gao, Bei ^c   Dong, Shuhong ^a,b   Zhang, Yingqi ^d   Wu, Yongjie ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b Key Laboratory of Preclinical Study for New Drugs of Gansu Province   (China)

^c GANSU PROVINCIAL HOSPITAL   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti tumor activity; Antibodies; Binding; Immunogenicity; Neutralizing; RhIFN 2a NGR

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2A INTERFERON ASPARAGINYLGLYCYLARGININE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; EXPERIMENTAL MONKEY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; INTERFERON ALFA-2A; LUNG NEOPLASMS; MACACA MULATTA; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MACACA MULATTA; MURINAE; RATTUS;

EID: 79955986954     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2011.02.007     Document Type: Article

References (20)

1. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
2. Bugelski P.J., Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Ther. 2004, 6:10-16.
3. Caraceni A., Gangeri L., Martini C., Belli F., Brunelli C., Baldini M., Mascheroni L., Lenisa L., Cascinelli N. Neurotoxicity of interferon alfa in melanoma therapy: results from a randomized controlled trial. Cancer 1998, 83:482-489.
4. Curnis F., Arrigoni G., Sacchi A., Fischetti L., Arap W., Pasqualini R., Corti A. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia and myeloid cells. Cancer Res. 2002, 62:867-874.
5. Gutterman J.U. Cytokine therapeutics: lessons from interferon-a. Proc. Natl. Acad. Sci. USA 1994, 91:1198-1205.
6. Hölig P., Bach M., Völkel T., Nahde T., Hoffmann S., Müller R., Kontermann R.E. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng. Des. Sel. 2004, 17:433-441.
7. Meng J., Yan Z., Wu Y., Gao M., Li W., Gao F., Wang H., Han W., Zhang Y. Preclinical safety evaluation of IFNa2a-NGR. Regul. Toxicol. Pharmacol. 2008, 50:294-302.
8. Meng J., Yan Z., Wu J., Li L., Xue X., Li M., Li W., Hao Q., Wan Y., Qin X., Zhang C., You Y., Han W., Zhang Y. High yield expression, purification and characterization of tumor-targeted interferon-a2a. Cytotherapy 2007, 9:60-68.
9. Motzer R.J., Murphy B.A., Bacik J., Schwartz L.H., Nanus D.M., Mariani T., Loehrer P., Wilding G., Fairclough D.L., Cella D., Mazumdar M. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J. Clin. Oncol. 2000, 16:2972-2980.
10. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., Ashmun R.A., Shapiro L.H., Arap W., Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000, 60:722-727.
11. Pestka S., Langer J.A., Zoon K.C., Samuel C.E. Interferons and their actions. Annu. Rev. Biochem. 1987, 56:727-777.
12. Sacchi A., Gasparri A., Curnis F., Bellone M., Corti A. Crucial role for interferon γ in the synergism between tumor vasculature-targeted tumor necrosis factor α (NGR-TNF) and doxorubicin. Cancer Res. 2004, 64:7150-7155.
13. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 2000, 1:457-462.
14. Shankar G., Shores E., Wagner C., Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 2006, 24:274-280.
15. Shipp M.A., Look A.T. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key. Blood 1993, 82:1052-1070.
16. Sliver R.T., Woolf S.H., Hehlmann R. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and alloeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999, 94:1517-1536.
17. Wadler S. The role of interferons in the treatment of solid tumors. Cancer 1992, 70:949-958.
18. Wang H., Yan Z., Shi J., Han W., Zhang Y. Expression, purification, and characterization of a neovasculature targeted rmhTNF-α in Escherichia coli. Protein Exp. Purif. 2006, 45:60-65.
19. Wierda D., Smith H.W., Zwickl C.M. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 2001, 158:71-74.
20. Yamada S., Takada K., Tsuchida S., Teramoto A., Shishiba Y. A study of anterior pituitary hormone secretion in patients with glioma receiving interferon-beta treatment. Endocr. J. 1996, 43:335-338.